Virtual Reality Digital Therapeutics for Seasonal Affective Disorder
VR-SAD
Effectiveness of Virtual Reality Digital Therapeutics for Seasonal Affective Disorder.
1 other identifier
interventional
60
0 countries
N/A
Brief Summary
Seasonal Affective Disorder (SAD) is commonly treated with bright light therapy. Virtual reality (VR) is an immersive computer-generated environment, which has been used to treat mental health difficulties, such as depression, social anxiety and stress. This study aims to compare the use of VR with bright light therapy in treating SAD. Participants will be randomly allocated to either the VR condition or the light box condition and instructed to use the respective device every day for 14 days.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2025
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 28, 2025
CompletedFirst Posted
Study publicly available on registry
September 8, 2025
CompletedStudy Start
First participant enrolled
October 27, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
ExpectedSeptember 8, 2025
September 1, 2025
5 months
August 28, 2025
September 4, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in levels of mood and depressive symptoms
Assessed by standardised psychological scales (Patient Health Questionnaire-9 (total score ranges from 0 to 27 with higher scores indication depression severity) and Positive and Negative Affect Schedule-Short Form (scores range from 10 to 50, with higher scores on the Positive Affect scale representing higher levels of positive affect, and higher scores on the Negative Affect scale representing higher levels of negative affect) and Visual Analogue Scales (0 to 100% with higher scores indicating better mood).
From baseline (day 1 to 7) to follow-up (day 28) of treatment
Secondary Outcomes (1)
Participant engagement, experience and satisfaction of the intervention
From baseline (day 1 to 7) to end of follow-up (day 28) treatment
Study Arms (2)
Virtual reality (VR) intervention
EXPERIMENTAL10-min VR intervention
Light Box (LB) intervention
ACTIVE COMPARATOR30-min LB intervention
Interventions
10-min VR intervention, once a day, everyday for 14 days.
30-min LB intervention once a day, everyday for 14 days.
Eligibility Criteria
You may qualify if:
- fluent in English and capable of giving informed consent
- or older
- resident in the United Kingdom and
- able to access internet and attend Anglia Ruskin University's Cambridge campus
- must self-identify or have been diagnosed with SAD, with moderate to severe symptoms
You may not qualify if:
- declared suffering from epilepsy (due to the risk that seizures may be triggered by VR use).
- currently using photosensitizing medications or have significant retinal pathology, due to potentially detrimental effects of light box use. For other ophthalmologic conditions, consultation with an ophthalmologist will be recommended.
- currently receiving active treatment for SAD, including antidepressant medication (less than 3 months), bright light treatment, or psychotherapy (e.g. CBT for seasonal affective disorder).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Anglia Ruskin Universitylead
- Reneural Technologies Ltd.collaborator
- Aerial Icon Ltd.collaborator
- Innovate UK, UKRIcollaborator
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Debora Vasconcelos e Sa, PhD
Anglia Ruskin University
- STUDY DIRECTOR
Jane Scott, PhD
Anglia Ruskin University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
August 28, 2025
First Posted
September 8, 2025
Study Start
October 27, 2025
Primary Completion
March 31, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
September 8, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ANALYTIC CODE
- Time Frame
- Upon study completion December 2026.
- Access Criteria
- Findings from this study will be submitted for publication in peer-reviewed journals and anonymised findings will be included in an online data repository (e.g., Figshare; Open Science Foundation).
This study will be written up to be published in peer-reviewed journals and anonymised data will be submitted to an online data repository (e.g., Figshare; Open Science Foundation).